Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing

BACKGROUND: Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated in several types of cancer, affecting the clinical response to EGFR inhibitors. Mutations in the EGFR kinase domain predict sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib i...

Descripción completa

Detalles Bibliográficos
Autores principales: Borràs, Emma, Jurado, Ismael, Hernan, Imma, Gamundi, María José, Dias, Miguel, Martí, Isabel, Mañé, Begoña, Arcusa, Àngels, Agúndez, José AG, Blanca, Miguel, Carballo, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192787/
https://www.ncbi.nlm.nih.gov/pubmed/21943394
http://dx.doi.org/10.1186/1471-2407-11-406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192787/
https://www.ncbi.nlm.nih.gov/pubmed/21943394
http://dx.doi.org/10.1186/1471-2407-11-406

Ejemplares similares